Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Dividends declared (per SOCE filings): FY2022 106 · FY2023 274 · FY2024 857 — 3-yr total 1,237
Operates in Pharma. Per the activity note to the FY2024 annual report, the company wholesales and manufactures food additives and dyes.
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|---|---|
| 737 | 1,567 | 1,891 | 2,398 | 3,342 | 3,503 | 3,276 | +28.2% | |
| Total COGS | 451 | 929 | 1,030 | 1,428 | 2,425 | 2,209 | 1,998 | +28.2% |
| Gross Profit | 287 | 638 | 861 | 971 | 916 | 1,294 | 1,278 | +28.3% |
| Gross Margin | 38.9% | 40.7% | 45.5% | 40.5% | 27.4% | 36.9% | 39.0% | |
| Other Operating Income | 0 | 0 | 7 | 6 | 0 | 0 | 0 | -19.5% |
| 199 | 412 | 395 | 483 | 753 | 882 | 701 | +23.4% | |
| EBITDA | 88 | 226 | 473 | 493 | 164 | 412 | 576 | +36.7% |
| EBITDA Margin | 12.0% | 14.4% | 25.0% | 20.6% | 4.9% | 11.8% | 17.6% | |
| Total D&A | 28 | 31 | 32 | 32 | 15 | 24 | 14 | -10.6% |
| EBIT / Operating Income | 60 | 194 | 441 | 461 | 149 | 388 | 562 | +45.1% |
| Total Interest Income | 5 | 0 | 0 | 0 | 0 | 0 | 2 | -15.0% |
| Total Interest Expense | 0 | 6 | 0 | 13 | 11 | 13 | 23 | +31.7% |
| 32 | 5 | 15 | 24 | 48 | 33 | 25 | nmf | |
| Profit Before Tax | 33 | 183 | 456 | 423 | 185 | 408 | 567 | +60.4% |
| Total Income Tax | 0 | 0 | 0 | 0 | 19 | 48 | 151 | +184.5% |
| Net Profit / (Loss) | 33 | 220 | 449 | 417 | 160 | 360 | 415 | +52.4% |
| Net Margin | 4.5% | 14.1% | 23.7% | 17.4% | 4.8% | 10.3% | 12.7% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →